Status:
COMPLETED
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 po...
Eligibility Criteria
Inclusion
- Histologically confirmed, CD20+ DLBCL or CD20+ follicular non-Hodgkin's lymphoma (NHL) Grade 1, 2 or 3a, according to the World Health Organization (WHO) classification system
- Currently being treated with rituximab intravenously (IV) in the Induction or Maintenance period, having received at least one full dose of rituximab IV, defined as standard full dose of rituximab IV 375 milligrams per square-meter (mg/m\^2) administered without interruption or early discontinuation (i.e. tolerability issues)
- Expectation and current ability for the participant to receive at least 4 additional cycles of treatment during the Induction period or 6 additional cycles of treatment during the Maintenance period (participants with follicular NHL)
- An International Prognostic Index (IPI) score of 1-4 or IPI score of 0 with bulky disease, defined as one lesion greater than or equal to (\>=) 7.5 centimeters (cm), or Follicular Lymphoma International Prognostic Index (FLIPI) (low, intermediate or high risk) assessed before the first rituximab IV administration in Induction period
- At least one bi-dimensionally measurable lesion defined as \>=1.5 cm in its largest dimension on computed tomography (CT) scan
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\<=) 3
Exclusion
- Transformed lymphoma or FL IIIB
- Primary central nervous system lymphoma, histologic evidence of transformation to a Burkitt lymphoma, primary effusion lymphoma, primary mediastinal DLBCL, DLBCL of the testis, or primary cutaneous DLBCL
- History of other malignancy
- Ongoing corticosteroid use greater than (\>) 30 milligrams per day (mg/day) of prednisone or equivalent
- Inadequate renal, hematologic, or hepatic function
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
- Contraindications to any of the individual components of standard chemotherapy
- Other serious underlying medical conditions, which, in the Investigator's judgement, could impair the ability of the participant to participate in the study
- Recent major surgery (within 4 weeks prior to dosing, other than for diagnosis)
- Active hepatitis B virus (HBV), active hepatitis C virus (HCV) infection, or human immunodeficiency virus (HIV) infection
Key Trial Info
Start Date :
July 31 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2019
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT01889069
Start Date
July 31 2013
End Date
May 28 2019
Last Update
August 13 2020
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
Bari, Apulia, Italy, 70124
2
Azienda ospedaliera oo rr di foggi; Hematology
Foggia, Apulia, Italy, 71100
3
Irccs Crob
Rionero in Vulture, Basilicate, Italy, 85028
4
Azienda Ospedaliera Bianchi-Melacrino-Morelli; Unità Operativa di Ematologia
Reggio Calabria, Calabria, Italy, 89100